Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Amgen Inc. (AMGN) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (638)	9/9/1998 8:51:00 AM
From: Biomaven	Read Replies (1) \| Respond to of 1906

John, Have you looked at REGN's Axokine? go2net.newsalert.com Seems to activate the same pathway as leptin, but works in leptin-resistant mice. REGN looks cheap at these levels, and would be an umpteen-bagger if Axokine works for obesity. Peter

To: Dr. John M. de Castro who wrote (638)	9/9/1998 12:07:00 PM
From: Lel H	Respond to of 1906

Dr de Castro, thanks for your report on the leptin results. They do sound discouraging. Could you provide the abstract, or does it just make vague reference to their results? Thanks. I would also appreciate more detailed data, if you have the time to provide it. I am sadly undereducated in the leptin field. Is leptin a freely-circulating peptide? As I understand, leptin receptors are located predominantly in the brain. Perhaps injection of leptin into non-native locations would result in the generation of antibodies, especially in high doses. I know from personal experience that rabbits will readily generate antibodies against recombinant rabbit proteins. Maybe a similar thing is happening in the leptin test subjects. Best wishes, Lel